
Please try another search
(Reuters) -British drugmaker GSK on Friday said it sold 240 million shares in its consumer healthcare business Haleon at 335 pence per share, raising about 804 million pounds ($1.01 billion).
Haleon, the world's biggest standalone consumer health company, comprising assets from GSK and Pfizer (NYSE:PFE), sells non-prescription drugs, vitamins and oral care products.
The sale price represents a 2.3% discount to Haleon's closing price of 342.85 pence on Thursday and lowers the stake of GSK, the second largest shareholder, to 10.3%.
Haleon shares were up 1.6% at 348 pence in early trade on Friday.
Last week, the firm reported quarterly profit below expectations as higher costs squeezed margins.
Sensodyne maker Haleon was formed in July 2019 as GSK and Pfizer merged their consumer healthcare businesses. It was spun out and listed on the London Stock Exchange in July 2022.
GSK and Pfizer have agreed to not sell any further Haleon shares for 60 days.
Pfizer told the Financial Times newspaper last week that it intends to offload its stake in a "slow and methodical" manner within months.
($1 = 0.7923 pounds)
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.